Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma

Kaohsiung J Med Sci. 2011 Dec;27(12):554-9. doi: 10.1016/j.kjms.2011.06.029. Epub 2011 Nov 25.

Abstract

The purpose of this study was to investigate the potential risk factors for the reactivation of the replication of hepatitis B virus (HBV) and hepatitis C virus (HCV) after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma. Forty-four hepatocellular carcinoma patients treated by TACE using epirubicin plus mitomycin C were studied. Serum HBV DNA (n=17) and HCV RNA (n=27) levels were measured 1 day before and 3 months after TACE. Plasma concentrations of chemotherapeutic agents were determined at 1 hour and 72 hours after TACE. A total of 29 patients (n=13 for chronic hepatitis Band n=16 for chronic hepatitis C) showed significant changes of the viral loads after TACE. Patients with increased viral loads after TACE were older (p=0.041), had higher incidence of pre-TACE white blood cell counts being less than normal limit (p=0.023), and had higher plasma mitomycin C concentrations (p=0.039) than those in patients with decreased viral loads. Analysis by multiple logistic regressions using age, decreased or normal pre-TACE white blood cell counts, mitomycin C concentrations >3.95 ng/mL adopted by receiver operating characteristic curve (p=0.037), and epirubicin concentrations have shown that decreased pre-TACE white blood cell counts was the only significant factor associated with increased viral loads after TACE (p=0.048). In conclusion, patients with decreased pre-TACE white blood cell counts have a potential risk for the reactivation of the replication of HBV or HCV after TACE.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / therapy*
  • Carcinoma, Hepatocellular / virology
  • Chemoembolization, Therapeutic*
  • DNA, Viral / blood
  • Epirubicin / administration & dosage
  • Female
  • Hepacivirus / physiology*
  • Hepatitis B virus / physiology*
  • Hepatitis B, Chronic / blood
  • Hepatitis B, Chronic / virology*
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / virology*
  • Humans
  • Leukocyte Count
  • Liver Neoplasms / blood
  • Liver Neoplasms / therapy*
  • Liver Neoplasms / virology
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage
  • Odds Ratio
  • RNA, Viral / blood
  • ROC Curve
  • Risk Factors
  • Viral Load / drug effects
  • Virus Activation*
  • Virus Replication*

Substances

  • DNA, Viral
  • RNA, Viral
  • Epirubicin
  • Mitomycin